title: Secretion of Flagellar Proteins by the Pseudomonas aeruginosa Type III Secretion-Injectisome System.
abstract: The opportunistic pathogen Pseudomonas aeruginosa utilizes an injectisome-type III secretion system (injectisome-T3SS) to elicit cytotoxicity toward epithelial cells and macrophages. Macrophage killing results from the cytotoxic properties of the translocated effector proteins (ExoS, ExoT, ExoU, and ExoY) and inflammasome-mediated induction of pyroptosis. Inflammasome activation can occur following Nlrc4-mediated recognition of cytosolic translocated flagellin (FliC). In the present study, we demonstrate that FliC is a secretion substrate of both the injectisome- and flagellum-associated T3SSs. Molecular analyses indicate that the first 20 amino-terminal residues of FliC are sufficient for secretion by the injectisome-T3SS and that the first 100 residues are sufficient for translocation of FliC into host cells. Although maximal inflammasome activation requires FliC, activation can also occur in the absence of FliC. This prompted us to examine whether other flagellar components might also be translocated into cells to elicit inflammasome activation. Indeed, we find that the flagellar cap (FliD), hook-associated (FlgK and FlgL), hook (FlgE), and rod (FlgE) proteins are secretion substrates of the injectisome-T3SS. None of these proteins, however, result in increased inflammasome activation when they are overexpressed in a fliC mutant and appear to be translocated into host cells. While a role in inflammasome activation has been excluded, these data raise the possibility that flagellar components, which are highly conserved between different bacterial species, trigger other specific host responses from the extracellular milieu or contribute to the pathogenesis of P. aeruginosa.
  
  
  OBJECTIVE
  The inflammasome is a host defense mechanism that recognizes invading bacteria and triggers an inflammatory immune response. The opportunistic pathogen P. aeruginosa produces both inflammasome agonists and antagonists. In this study, we demonstrate that overexpression of an agonist suppresses the activity of an antagonist, thereby resulting in inflammasome activation. Since the relative expression levels of agonists and antagonists likely vary between strains, these differences could be important predictors of whether a particular P. aeruginosa strain elicits inflammasome activation.
authors.affiliation: Department of Internal Medicine, Division of Infectious Disease, University of Iowa, Iowa City, Iowa, USA.
authors.forename: Dilek
authors.initials: D
authors.lastname: Ince
authors.affiliation: Department of Internal Medicine, Division of Infectious Disease, University of Iowa, Iowa City, Iowa, USA Veterans Affairs Medical Center, Iowa City, Iowa, USA.
authors.forename: Fayyaz S
authors.initials: FS
authors.lastname: Sutterwala
authors.affiliation: Department of Microbiology, University of Iowa, Iowa City, Iowa, USA tim-yahr@uiowa.edu.
authors.forename: Timothy L
authors.initials: TL
authors.lastname: Yahr
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D002460:Cell Line; D005408:Flagellin / Q000235:genetics / Q000378:metabolism*; D015964:Gene Expression Regulation, Bacterial / Q000502:physiology*; D006801:Humans; D058847:Inflammasomes / Q000502:physiology; D053583:Interleukin-1beta / Q000378:metabolism; D008264:Macrophages / Q000502:physiology; D051379:Mice; D009154:Mutation; D010957:Plasmids; D021381:Protein Transport; D011550:Pseudomonas aeruginosa / Q000378:metabolism*
chemical_list: D058847:Inflammasomes; D053583:Interleukin-1beta; D005408:Flagellin
references.citation: Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3076-80
references.pmid: 20133635
references.citation: Proc Natl Acad Sci U S A. 2010 Oct 12;107(41):17745-50
references.pmid: 20876096
references.citation: Cell Microbiol. 2012 Feb;14(2):149-54
references.pmid: 21995284
references.citation: Gene. 1998 May 28;212(1):77-86
references.pmid: 9661666
references.citation: Mol Biosyst. 2008 Nov;4(11):1105-15
references.pmid: 18931786
references.citation: Nat Immunol. 2006 Jun;7(6):576-82
references.pmid: 16648852
references.citation: J Bacteriol. 1991 Apr;173(7):2301-10
references.pmid: 1848842
references.citation: Infect Immun. 2006 Jun;74(6):3334-41
references.pmid: 16714561
references.citation: Infect Immun. 2005 Mar;73(3):1695-705
references.pmid: 15731070
references.citation: Infect Immun. 2003 Apr;71(4):1630-4
references.pmid: 12654774
references.citation: Mol Microbiol. 2010 May;76(4):918-31
references.pmid: 20398207
references.citation: Biochim Biophys Acta. 2004 Nov 11;1694(1-3):207-17
references.pmid: 15546667
references.citation: J Cell Mol Med. 2008 Sep-Oct;12(5A):1767-76
references.pmid: 18081695
references.citation: Mol Microbiol. 1997 Nov;26(4):621-9
references.pmid: 9427393
references.citation: Infect Immun. 2007 Sep;75(9):4432-9
references.pmid: 17635873
references.citation: Nat Immunol. 2006 Jun;7(6):569-75
references.pmid: 16648853
references.citation: Nat Immunol. 2006 Mar;7(3):318-25
references.pmid: 16444259
references.citation: J Biol Chem. 2007 Nov 23;282(47):33897-901
references.pmid: 17911114
references.citation: Clin Immunol. 2009 Jan;130(1):2-6
references.pmid: 18819842
references.citation: Nature. 2011 Sep 29;477(7366):592-5
references.pmid: 21874021
references.citation: Front Microbiol. 2011 Apr 25;2:89
references.pmid: 21833328
references.citation: Cytokine. 2008 Sep;43(3):368-73
references.pmid: 18715799
references.citation: Infect Immun. 1994 Feb;62(2):554-63
references.pmid: 8300213
references.citation: Nat Med. 1999 Apr;5(4):392-8
references.pmid: 10202927
references.citation: Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):11998-2002
references.pmid: 8618831
references.citation: Ann Clin Microbiol Antimicrob. 2005;4:22
references.pmid: 16375761
references.citation: Proc Natl Acad Sci U S A. 2012 Jan 24;109(4):1275-80
references.pmid: 22232685
references.citation: Biochim Biophys Acta. 2008 Sep;1778(9):1851-8
references.pmid: 17719558
references.citation: Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):14408-13
references.pmid: 23940371
references.citation: Eur J Immunol. 2007 Nov;37(11):3030-9
references.pmid: 17935074
references.citation: Nat Rev Microbiol. 2009 Sep;7(9):654-65
references.pmid: 19680249
references.citation: PLoS Pathog. 2007 Aug 10;3(8):e111
references.pmid: 17696608
references.citation: J Clin Invest. 2013 Apr;123(4):1630-7
references.pmid: 23478406
references.citation: Contrib Microbiol. 2008;15:45-60
references.pmid: 18511855
references.citation: Nat Rev Drug Discov. 2009 Jun;8(6):465-79
references.pmid: 19483708
references.citation: Nature. 2011 Sep 29;477(7366):596-600
references.pmid: 21918512
references.citation: Nature. 2004 Jul 8;430(6996):213-8
references.pmid: 15190255
references.citation: Mol Microbiol. 2008 May;68(3):657-71
references.pmid: 18373522
references.citation: Am J Respir Crit Care Med. 2014 Apr 1;189(7):799-811
references.pmid: 24555512
references.citation: Biochem Biophys Res Commun. 2006 Jun 23;345(1):93-8
references.pmid: 16674914
references.citation: J Exp Med. 2007 Dec 24;204(13):3235-45
references.pmid: 18070936
references.citation: Cell Microbiol. 2011 Mar;13(3):388-401
references.pmid: 20955240
references.citation: Mol Cell. 2002 Aug;10(2):417-26
references.pmid: 12191486
references.citation: Curr Opin Immunol. 2008 Aug;20(4):377-82
references.pmid: 18585455
references.citation: J Bacteriol. 2007 Apr;189(8):3124-32
references.pmid: 17307856
references.citation: BMC Microbiol. 2009;9:30
references.pmid: 19200386
references.citation: Immunity. 2008 Mar;28(3):285-7
references.pmid: 18341998
references.citation: Mol Microbiol. 2002 Nov;46(4):1123-33
references.pmid: 12421316
references.citation: Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2562-7
references.pmid: 18256184
references.citation: Nat Immunol. 2008 Oct;9(10):1171-8
references.pmid: 18724372
references.citation: Dev Cell. 2003 Feb;4(2):253-63
references.pmid: 12586068
references.citation: PLoS Pathog. 2006 Mar;2(3):e18
references.pmid: 16552444